Ozekibart
- Generic Name
- Ozekibart
- Drug Type
- Biotech
- CAS Number
- 2539847-03-3
- Unique Ingredient Identifier
- R0GA5221D4
- Background
Ozekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.
Inhibrx's Ozekibart Shows Promise in Phase 1 Colorectal Cancer Trial
• Inhibrx Biosciences announced preliminary Phase 1 data for ozekibart (INBRX-109) combined with FOLFIRI in advanced colorectal adenocarcinoma, presented at ASCO GI Cancers Symposium.
• The trial showed one complete response, three partial responses, and six cases of stable disease in 10 evaluable patients, with 46.2% achieving durable disease control.
• Ozekibart-related adverse events were mostly low-grade, with the most common being nausea, increased alanine aminotransferase, diarrhea, and fatigue.
• An expansion cohort enrolling up to 50 patients with 2-3 prior lines of therapy has been initiated to validate these findings, with data expected in Q3 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath